Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Neurocrine Biosciences (NBIX) Leases (2019 - 2026)

Neurocrine Biosciences filings provide 7 years of Leases readings, the most recent being $455.4 million for Q4 2025.

  • On a quarterly basis, Leases fell 10.6% to $455.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $455.4 million, a 10.6% decrease, with the full-year FY2025 number at $455.4 million, down 10.6% from a year prior.
  • Leases hit $455.4 million in Q4 2025 for Neurocrine Biosciences, down from $468.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $509.4 million in Q4 2024 to a low of $80.8 million in Q3 2023.
  • Median Leases over the past 5 years was $99.1 million (2021), compared with a mean of $221.1 million.
  • Biggest five-year swings in Leases: dropped 10.88% in 2023 and later skyrocketed 220.85% in 2024.
  • Neurocrine Biosciences' Leases stood at $97.2 million in 2021, then fell by 10.49% to $87.0 million in 2022, then surged by 128.74% to $199.0 million in 2023, then soared by 155.98% to $509.4 million in 2024, then dropped by 10.6% to $455.4 million in 2025.
  • The last three reported values for Leases were $455.4 million (Q4 2025), $468.9 million (Q3 2025), and $492.3 million (Q2 2025) per Business Quant data.